Ultrasonography surveillance improves prognosis of patients with hepatocellular carcinoma

  • Authors:
    • Hiroka Yamago
    • Atsushi Hiraoka
    • Taisei Murakami
    • Hirofumi Izumoto
    • Hidetaro Ueki
    • Marie Ochi
    • Toshihiko Aibiki
    • Tomonari Okudaira
    • Ryuichiro Iwasaki
    • Yoshifumi Suga
    • Kenichiro Mori
    • Hideki Miyata
    • Eiji Tsubouchi
    • Masato Kishida
    • Masashi Hirooka
    • Masanori Abe
    • Bunzo Matsuura
    • Tomoyuki Ninomiya
    • Yoichi Hiasa
    • Kojiro Michitaka
  • View Affiliations

  • Published online on: June 25, 2019     https://doi.org/10.3892/mco.2019.1888
  • Pages: 325-330
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To examine the effectiveness of ultrasonography (US) for hepatocellular carcinoma (HCC) surveillance, the prognosis of HCC patients who underwent such screening at an expert medical institution or at general clinics were analyzed, as well as those without US surveillance. From October 2006 to December 2014, 872 patients with naïve HCC were enrolled and divided into the surveillance (S)‑group (n=398), who underwent follow‑up examinations with US, and the non‑S group (n=474). The S‑group was further subdivided into patients who underwent follow‑up surveillance at Ehime Prefectural Central Hospital, an expert medical institution (SE‑group, n=189), and those who received surveillance at general clinics (SG‑group, n=209). Prognosis and clinical characteristics were analyzed. In the non‑S group, the frequency of patients without viral hepatitis (NBNC‑HCC) and Tumor, Node, Metastasis stage was greater. As a result, the median survival time (MST) of the non‑S group was reduced, compared with the S group (non‑S group, 34.1 vs. S group, 68.2 months; P<0.001). Tumor size was significantly different between the SE‑ and SG‑groups (SE‑group, 2.0±1.0 vs. SG‑group, 2.5±1.3 cm; P<0.001), whereas tumor number (SE‑group: 1.5±1.1 vs. SG‑group, 1.7±1.2; P=0.164) and MST (SE‑group, 72.1 vs. SG‑group, 67.1 months; P=0.931) were not significantly different. Surveillance performed at either an expert medical institution or general clinic improved the prognosis of HCC patients. Dissemination of findings demonstrating the importance of surveillance for HCC to all clinicians as well as patients with chronic liver disease is important, and establishment of an effective surveillance strategy for NBNC‑HCC is required.

References

1 

Song TJ, Ip EW and Fong Y: Hepatocellular carcinoma: Current surgical management. Gastroenterology 127 (5 Suppl 1). S248–S260. 2004.

2 

Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI

3 

Hiraoka A, Hidaka S, Shimizu Y, Utsunomiya H, Imai Y, Tatsukawa H, Tazuya N, Yamago H, Yorimitsu N, Tanihira T, et al: Recent trends of Japanese hepatocellular carcinoma due to HCV in aging society. Hepatogastroenterology. 59:1893–1895. 2012.PubMed/NCBI

4 

Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A and Tanaka J: Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic. J Gastroenterol Hepatol. 32:451–458. 2017. View Article : Google Scholar : PubMed/NCBI

5 

Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y and Matsunaga T: Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score. Hepatology. 40:1396–1405. 2004. View Article : Google Scholar : PubMed/NCBI

6 

Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ueki H, Kaneto M, Aibiki T, Okudaira T, Kawakami T, et al: Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 31:1031–1036. 2016. View Article : Google Scholar : PubMed/NCBI

7 

Hiraoka A, Kumada T, Kudo M, Hirooka M, Tsuji K, Itobayashi E, Kariyama K, Ishikawa T, Tajiri K, Ochi H, et al: Albumin-Bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan society of hepatology: A comparison with the liver damage and child-pugh classifications. Liver Cancer. 6:204–215. 2017. View Article : Google Scholar : PubMed/NCBI

8 

Miyagawa S, Makuuchi M, Kawasaki S and Kakazu T: Criteria for safe hepatic resection. Am J Surg. 169:589–594. 1995. View Article : Google Scholar : PubMed/NCBI

9 

Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, et al: Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 107:569–577; quiz 578. 2012. View Article : Google Scholar : PubMed/NCBI

10 

Hiraoka A, Michitaka K, Horiike N, Hidaka S, Uehara T, Ichikawa S, Hasebe A, Miyamoto Y, Ninomiya T, Sogabe I, et al: Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients. J Gastroenterol Hepatol. 25:403–407. 2010. View Article : Google Scholar : PubMed/NCBI

11 

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI

12 

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 389:56–66. 2017. View Article : Google Scholar : PubMed/NCBI

13 

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet. 391:1163–1173. 2018. View Article : Google Scholar : PubMed/NCBI

14 

Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Itobayashi E, Shimada N, Tajiri K, Tsuji K, Ishikawa T, Ochi H, et al: Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis. Hepatol Res. 49:111–117. 2019.PubMed/NCBI

15 

Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M and Sherman M: Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: A cost effectiveness analysis. Gut. 48:251–259. 2001. View Article : Google Scholar : PubMed/NCBI

16 

Tanaka H, Nouso K, Kobashi H, Kobayashi Y, Nakamura S, Miyake Y, Ohnishi H, Miyoshi K, Iwado S, Iwasaki Y, et al: Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. Liver Int. 26:543–551. 2006. View Article : Google Scholar : PubMed/NCBI

17 

Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, Matsuyama Y, Okazaki M, Okita K, Omata M, et al: Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 38:37–51. 2008. View Article : Google Scholar : PubMed/NCBI

18 

Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, et al: Evidence-based clinical practice guidelines for hepatocellular carcinoma: The Japan society of hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res. 45:2015. View Article : Google Scholar

19 

Sano K, Ichikawa T, Motosugi U, Sou H, Muhi AM, Matsuda M, Nakano M, Sakamoto M, Nakazawa T, Asakawa M, et al: Imaging study of early hepatocellular carcinoma: Usefulness of gadoxetic acid-enhanced MR imaging. Radiology. 261:834–844. 2011. View Article : Google Scholar : PubMed/NCBI

20 

Bruix J and Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases, : Management of hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005. View Article : Google Scholar : PubMed/NCBI

21 

Hiraoka A, Hiasa Y, Onji M and Michitaka K: New contrast enhanced ultrasonography agent: Impact of Sonazoid on radiofrequency ablation. J Gastroenterol Hepatol. 26:616–618. 2011. View Article : Google Scholar : PubMed/NCBI

22 

Hiraoka A, Ichiryu M, Tazuya N, Ochi H, Tanabe A, Nakahara H, Hidaka S, Uehara T, Ichikawa S, Hasebe A, et al: Clinical translation in the treatment of hepatocellular carcinoma following the introduction of contrast-enhanced ultrasonography with Sonazoid. Oncol Lett. 1:57–61. 2010. View Article : Google Scholar : PubMed/NCBI

23 

The Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 6th. Kanehara; Tokyo: 26. 2015

24 

Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI

25 

Kan M, Hiraoka A, Uehara T, Hidaka S, Ichiryu M, Nakahara H, Ochi H, Tanabe A, Kodama A, Hasebe A, et al: Evaluation of contrast-enhanced ultrasonography using perfluorobutane [Sonazoid(®)] in patients with small hepatocellular carcinoma: Comparison with dynamic computed tomography. Oncol Lett. 1:485–488. 2010. View Article : Google Scholar : PubMed/NCBI

26 

Hiraoka A, Horiike N, Yamashita Y, Koizumi Y, Doi K, Yamamoto Y, Hasebe A, Ichikawa S, Yano M, Miyamoto Y, et al: Efficacy of radiofrequency ablation therapy compared to surgical resection in 164 patients in Japan with single hepatocellular carcinoma smaller than 3 cm, along with report of complications. Hepatogastroenterology. 55:2171–2174. 2008.PubMed/NCBI

27 

Hirooka M, Iuchi H, Kumagi T, Shigematsu S, Hiraoka A, Uehara T, Kurose K, Horiike N and Onji M: Virtual sonographic radiofrequency ablation of hepatocellular carcinoma visualized on CT but not on conventional sonography. AJR Am J Roentgenol. 186 (5 Suppl):S255–S260. 2006. View Article : Google Scholar : PubMed/NCBI

28 

Uehara T, Hirooka M, Ishida K, Hiraoka A, Kumagi T, Kisaka Y, Hiasa Y and Onji M: Percutaneous ultrasound-guided radiofrequency ablation of hepatocellular carcinoma with artificially induced pleural effusion and ascites. J Gastroenterol. 42:306–311. 2007. View Article : Google Scholar : PubMed/NCBI

29 

Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, Su GL, Lok AS and Marrero JA: Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 21:793–799. 2012. View Article : Google Scholar : PubMed/NCBI

30 

Zhang BH, Yang BH and Tang ZY: Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 130:417–422. 2004. View Article : Google Scholar : PubMed/NCBI

31 

Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC and Zhu YR: Screening for liver cancer: Results of a randomised controlled trial in Qidong, China. J Med Screen. 10:204–209. 2003. View Article : Google Scholar : PubMed/NCBI

32 

Costentin CE, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, et al: Compliance with hepatocellular carcinoma surveillance guidelines associated with increased lead-time adjusted survival of patients with compensated viral cirrhosis: A multi-center cohort study. Gastroenterology. 155:431–442.e10. 2018. View Article : Google Scholar : PubMed/NCBI

33 

Toyoda H, Kumada T, Tada T, Mizuno K, Hiraoka A, Tsuji K, Ishikawa T, Akita T and Tanaka J: Impact of hepatocellular carcinoma aetiology and liver function on the benefit of surveillance: A novel approach for the adjustment of lead-time bias. Liver Int. 38:2260–2268. 2018. View Article : Google Scholar : PubMed/NCBI

34 

Tateishi R, Okanoue T, Fujiwara N, Okita K, Kiyosawa K, Omata M, Kumada H, Hayashi N and Koike K: Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: A large retrospective multicenter cohort study. J Gastroenterol. 50:350–360. 2015. View Article : Google Scholar : PubMed/NCBI

35 

Urata Y, Yamasaki T, Saeki I, Iwai S, Kitahara M, Sawai Y, Tanaka K, Aoki T, Iwadou S, Fujita N, et al: Clinical characteristics and prognosis of non-B non-C hepatocellular carcinoma patients with modest alcohol consumption. Hepatol Res. 46:434–442. 2016. View Article : Google Scholar : PubMed/NCBI

36 

Hiraoka A, Ochi M, Matsuda R, Aibiki T, Okudaira T, Kawamura T, Yamago H, Nakahara H, Suga Y, Azemoto N, et al: Ultrasonography screening for hepatocellular carcinoma in Japanese patients with diabetes mellitus. J Diabetes. 8:640–646. 2016. View Article : Google Scholar : PubMed/NCBI

37 

Kolly P and Dufour JF: Surveillance for hepatocellular carcinoma in patients with NASH. Diagnostics (Basel). 6(pii): E222016. View Article : Google Scholar : PubMed/NCBI

38 

Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, et al: Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 43:1317–1325. 2006. View Article : Google Scholar : PubMed/NCBI

39 

Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H and Pol S: FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 46:32–36. 2007. View Article : Google Scholar : PubMed/NCBI

40 

Smajerova M, Petrasova H, Little J, Ovesna P, Andrasina T, Valek V, Nemcova E and Miklosova B: Contrast-enhanced ultrasonography in the evaluation of incidental focal liver lesions: A cost-effectiveness analysis. World J Gastroenterol. 22:8605–8614. 2016. View Article : Google Scholar : PubMed/NCBI

41 

Ogawa C, Minami Y, Morioka Y, Noda A, Arasawa S, Izuta M, Kubo A, Matsunaka T, Tamaki N, Shibatouge M and Kudo M: Virtual sonography for novice sonographers: Usefulness of SYNAPSE VINCENT® with pre-check imaging of tumor location. Oncology. 87 (Suppl 1):S50–S54. 2014. View Article : Google Scholar

Related Articles

Journal Cover

September 2019
Volume 11 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yamago, H., Hiraoka, A., Murakami, T., Izumoto, H., Ueki, H., Ochi, M. ... Michitaka, K. (2019). Ultrasonography surveillance improves prognosis of patients with hepatocellular carcinoma. Molecular and Clinical Oncology, 11, 325-330. https://doi.org/10.3892/mco.2019.1888
MLA
Yamago, H., Hiraoka, A., Murakami, T., Izumoto, H., Ueki, H., Ochi, M., Aibiki, T., Okudaira, T., Iwasaki, R., Suga, Y., Mori, K., Miyata, H., Tsubouchi, E., Kishida, M., Hirooka, M., Abe, M., Matsuura, B., Ninomiya, T., Hiasa, Y., Michitaka, K."Ultrasonography surveillance improves prognosis of patients with hepatocellular carcinoma". Molecular and Clinical Oncology 11.3 (2019): 325-330.
Chicago
Yamago, H., Hiraoka, A., Murakami, T., Izumoto, H., Ueki, H., Ochi, M., Aibiki, T., Okudaira, T., Iwasaki, R., Suga, Y., Mori, K., Miyata, H., Tsubouchi, E., Kishida, M., Hirooka, M., Abe, M., Matsuura, B., Ninomiya, T., Hiasa, Y., Michitaka, K."Ultrasonography surveillance improves prognosis of patients with hepatocellular carcinoma". Molecular and Clinical Oncology 11, no. 3 (2019): 325-330. https://doi.org/10.3892/mco.2019.1888